| Clinically isolated syndrome
Tascenso ODT vs Aubagio
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Tascenso Odt vs Aubagio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAubagio has a higher rate of injection site reactions vs Tascenso Odt based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Aubagio but not Tascenso Odt, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tascenso Odt
Aubagio
At A Glance
Oral
Daily
Sphingosine 1-phosphate receptor modulator
Oral
Daily
Pyrimidine synthesis inhibitor
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Adults and pediatric patients (10 years and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food; pediatric patients (10 years and older) weighing 40 kg or less: 0.25 mg orally once daily, with or without food.
Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 7 mg or 14 mg orally once daily; may be taken with or without food.
Contraindications
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within the last 6 months
- History or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome without a functioning pacemaker
- Baseline QTc interval >= 500 msec
- Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
- Previous hypersensitivity reaction to fingolimod or any excipient (including rash, urticaria, or angioedema)
- Concomitant use with other products containing fingolimod
- Severe hepatic impairment
- Pregnancy or females of reproductive potential not using effective contraception
- History of hypersensitivity reaction to teriflunomide, leflunomide, or any inactive ingredient (including anaphylaxis, angioedema, or serious skin reactions)
- Coadministration with leflunomide
Adverse Reactions
Most common (>=10%) Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, pain in extremity
Serious Bradyarrhythmia, AV blocks, infections, progressive multifocal leukoencephalopathy, macular edema, liver injury, posterior reversible encephalopathy syndrome, fetal risk, malignancies, hypersensitivity reactions
Postmarketing Hemolytic anemia, thrombocytopenia, liver injury, cryptococcal infections, HPV infection, PML, arthralgia, myalgia, PRES, seizures, melanoma, Merkel cell carcinoma, cutaneous T-cell lymphoma, Kaposi's sarcoma, squamous cell carcinoma, hypersensitivity
Most common (>=2% above placebo) Headache, increased alanine aminotransferase, diarrhea, alopecia, nausea, paresthesia, arthralgia, neutropenia, hypertension
Serious Hepatotoxicity, bone marrow effects/immunosuppression/infections, hypersensitivity reactions, serious skin reactions, DRESS, cutaneous or mucocutaneous ulcers and impaired wound healing, peripheral neuropathy, increased blood pressure, respiratory effects, pancreatitis (pediatric patients)
Postmarketing Thrombocytopenia, pancreatitis, colitis, drug-induced liver injury, anaphylaxis, angioedema, interstitial lung disease, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS, psoriasis (including pustular and nail), nail disorders, cutaneous or mucocutaneous ulcers, impaired wound healing
Pharmacology
Fingolimod is metabolized to fingolimod-phosphate, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts, thereby limiting lymphocyte migration into the central nervous system.
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme required for de novo pyrimidine synthesis, which may reduce the number of activated lymphocytes in the CNS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tascenso Odt
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Aubagio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (4/12)
UnitedHealthcare
Tascenso Odt
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Aubagio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Tascenso Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Aubagio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Tascenso OdtView full Tascenso Odt profile
AubagioView full Aubagio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.